USP7 and neoplasm: Studies have shown that cisplatin and paclitaxel activate the USP7/hnRNPA1 axis to promote CAF secretion of miR-522, which inhibits the activity of ALOX15 in tumor cells, reduces ROS production, and inhibits ferroptosis in tumor cells [114].